CA2129895A1 - Dosage des auto-anticorps et utilisation pour la surveillance des maladies humaines - Google Patents

Dosage des auto-anticorps et utilisation pour la surveillance des maladies humaines

Info

Publication number
CA2129895A1
CA2129895A1 CA 2129895 CA2129895A CA2129895A1 CA 2129895 A1 CA2129895 A1 CA 2129895A1 CA 2129895 CA2129895 CA 2129895 CA 2129895 A CA2129895 A CA 2129895A CA 2129895 A1 CA2129895 A1 CA 2129895A1
Authority
CA
Canada
Prior art keywords
ataa
cells
autoantibody
cell
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2129895
Other languages
English (en)
Inventor
Robert Perper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2129895A1 publication Critical patent/CA2129895A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2129895 1992-02-12 1993-02-01 Dosage des auto-anticorps et utilisation pour la surveillance des maladies humaines Abandoned CA2129895A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83569692A 1992-02-12 1992-02-12
US835,696 1992-02-12

Publications (1)

Publication Number Publication Date
CA2129895A1 true CA2129895A1 (fr) 1993-08-13

Family

ID=25270231

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2129895 Abandoned CA2129895A1 (fr) 1992-02-12 1993-02-01 Dosage des auto-anticorps et utilisation pour la surveillance des maladies humaines

Country Status (5)

Country Link
EP (1) EP0625909A4 (fr)
JP (1) JPH07504495A (fr)
AU (1) AU3603893A (fr)
CA (1) CA2129895A1 (fr)
WO (1) WO1993015759A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay

Also Published As

Publication number Publication date
EP0625909A4 (en) 1997-03-05
EP0625909A1 (fr) 1994-11-30
WO1993015759A1 (fr) 1993-08-19
AU3603893A (en) 1993-09-03
JPH07504495A (ja) 1995-05-18

Similar Documents

Publication Publication Date Title
Cui et al. Identification of pigment cell antigens defined by vitiligo antibodies
Romagnani Th1 and Th2 in human diseases
Körner et al. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting
Finkel et al. The thymus has two functionally distinct populations of immature αβ+ T cells: one population is deleted by ligation of αβTCR
KR100216097B1 (ko) 자가면역 및 악성종양질환 치료제로서의 t세포 수용체 펩티드
Kamath et al. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs
Genain et al. In healthy primates, circulating autoreactive T cells mediate autoimmune disease.
Holoshitz et al. Autoimmune encephalomyelitis (EAE) mediated or prevented by T lymphocyte lines directed against diverse antigenic determinants of myelin basic protein. Vaccination is determinant specific.
Detrick et al. Expression of HLA-DR antigen on retinal pigment epithelial cells in retinitis pigmentosa
Rittenhouse et al. Complement-mediated cytotoxic effects on pancreatic islets with sera from diabetic patients
Chou et al. Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides.
Neuberger et al. Antibodies to alcohol altered liver cell determinants in patients with alcoholic liver disease.
Mima et al. Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints.
JP2002531123A (ja) ヒトの乾癬を予防及び治療するための乾癬モデル動物
JPH06205671A (ja) 形質転換細胞の抽出および培養ならびにそれらに対する抗体の製造
Darabi et al. The third signal in T cell-mediated autoimmune disease?
Mor et al. Clinical modeling of T cell vaccination against autoimmune diseases in rats. Selection of antigen-specific T cells using a mitogen.
Foedinger et al. Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice
Haque et al. Transplacental transfer of rodent microfilariae induces antigen-specific tolerance in rats
Arnold Levels of peripheral T cell tolerance
US7087573B1 (en) Methods of inhibiting platelet anti-HLA alloimmune antibody responses with soluble 18 KDa CD40L
Aissaoui et al. Prevention of autoimmune attack by targeting specific T‐cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis
Birnbaum et al. Heat shock proteins and experimental autoimmune encephalomyelitis: II: environmental infection and extra-neuraxial inflammation alter the course of chronic relapsing encephalomyelitis
Whitaker-Menezes et al. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression
Tung et al. Discrepancy between Clq deviation and Raji cell tests in detection of circulating immune complexes in patients with leprosy

Legal Events

Date Code Title Description
FZDE Dead